Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
The US Food and Drug Administration (FDA) has approved a new clinical trial of a groundbreaking strategy using stem cells for the treatment of MS (multiple sclerosis).
Researchers from the Tisch MS Research Center of New York say the FDA has granted approval to begin early clinical investigation (phase 1 trial) of autologous neural stem cells in the treatment of MS.
Multiple sclerosis is a chronic disease that attacks the central nervous system (the spinal cord, optic nerves and brain). Common symptoms are numbness of the limbs, but more severe cases can lead to paralysis and blindness.
According to the Multiple Sclerosis Foundation, there are currently between 350,000 to 500,000 people in the US who have been diagnosed with MS, and 200 people are diagnosed with the disease every week.
The new regenerative strategy will involve using autologous, mesenchymal stem cell-derived neural progenitor cells (MSC-NPs), which will be harvested from the bone marrow of 20 MS patients who meet the criteria for the trial.
The stem cells will then be injected into the cerebrospinal fluid that surrounds the spinal cords of the patients.
The main objective of the clinical trial, the researchers say, is to determine the safety of the treatment, while the secondary objective is to measure the effectiveness.
The injections will be repeated at 3-month intervals, with their safety and efficacy frequently monitored through follow-up visits. After the final injection, patients will be monitored for up to 27 months.
Preclinical testing of this procedure showed that after injecting the stem cells, brain inflammation was reduced in seven MS patients, myelin was repaired (an insulating layer that forms around nerves), and protection of the neuronal structure and function of the brain was improved.
Dr. Saud Sadiq, senior research scientist at Tisch MS Research Center of New York, says:
"This study provides a hope that established disability may be reversed in MS."
Similar trials but with larger number of patients (phase 2) have already been under way in the UK. In 2011, UK scientists received £1 million from the MS Society and the UK Stem Cell Foundation (UKCSF) towards research investigating whether stem cells can slow, stop or reverse brain and spinal cord damage in MS patients.
Dr. Sadiq says of this most recent trial in the US:
"To my knowledge, this is the first FDA-approved stem cell trial in the United States to investigate direct injection of stem cells into the cerebrospinal fluid of MS patients, and represents an exciting advance in MS research and treatment."
The clinical trial will begin enrolling patients once ethical approval has been granted and funding secured.*
Written by Honor Whiteman
Copyright: Medical News Today
Not to be reproduced without the permission of Medical News Today.
* Questions about the study protocol, enrollment criteria, and other non-clinical matters should be directed to the Study Coordinators Daniel Koffler (dkoffler (at) tischms (dot) org or 646-557-3852) and Sydney Chirls (schirls (at) tischms (dot) org or 646-557-3860).
Visit our Multiple Sclerosis category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Whiteman, Honor. "Groundbreaking multiple sclerosis stem cell trial approved." Medical News Today. MediLexicon, Intl., 18 Aug. 2013. Web.
13 Dec. 2013. <http://www.medicalnewstoday.com/articles/264892>
Whiteman, H. (2013, August 18). "Groundbreaking multiple sclerosis stem cell trial approved." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Latest 8 opinions shown. For all opinions, click through to the full thread.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/articles/264892.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.